BIOS News and Press, BioPlus Acquisition Corp.

Study shows improved hand function using Carbonhand PR Newswire STOCKHOLM , March 13, 2024 /PRNewswire/ -- Today, a study on Improved physical function using a power-enhancing glove in persons with Inclusion Body Myositis was presented at the Global Conference ...

2023-10-04 10:35:52 ET More on BioPlus Acquisition Corp. Financial information for BioPlus Acquisition Corp SPAC BIOS to merge with cardiac device maker Avertix For further details see: SPAC BioPlus, Avertix terminate merger; BioPlus to liquidate

EATONTOWN, N.J. and NEW YORK, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Avertix Medical, Inc. (“Avertix” or the “Company”), formerly known as Angel Medical Systems, Inc., a company focused on improving long-term management and outcomes of high-risk coronary disease in ...

New York, NY, Oct. 04, 2023 (GLOBE NEWSWIRE) -- BioPlus Acquisition Corp. (“BIOS” or the “Company”) (Nasdaq: BIOS) announced today that (i) BIOS, Avertix Medical, Inc. and certain other parties have mutually agreed to terminate their previously announced business combi...

The Avertix Guardian™ System, the first and only FDA approved implantable heart attack warning system, now available at the Heart & Rhythm Institute of Trinity, extending their commitment to redefining cardiac care in the Tampa, FL area Dr. Luis R. Annoni-Suau, MD, FACC and D...

Recently served as Boston Scientific Executive Vice President and Global Chief Medical Officer Professor Meredith brings to Avertix over 35 years of cardiology experience and commitment to advancing cardiac care EATONTOWN, N.J., July 17, 2023 (GLOBE NEWSWIRE) -- Avertix Medi...

EATONTOWN, N.J. and ORLANDO, Fla., June 13, 2023 (GLOBE NEWSWIRE) -- Avertix Medical, Inc. (“Avertix” or the “Company”), formerly known as Angel Medical Systems, Inc., a company focused on improving long-term management and outcomes of high-risk coronary disease in...

- Transaction values Avertix at an enterprise value of $195 million - Avertix developed the Guardian™ System, the first and only FDA-approved solution designed to detect and warn patients of cardiac events, including silent heart attacks EATONTOWN, N.J. and NEW YORK, May 03, 20...

Summary The new January 2023 selections are the current top positive/negative forensic stocks based on combined scores from four different forensic algorithms. Both the 2022 January Positive Forensic portfolio beat the S&P 500 by +6.59% and the Negative Forensic portfolio beat by +2...

New York, NY, Dec. 02, 2021 (GLOBE NEWSWIRE) -- BioPlus Acquisition Corp. (the “Company”) announced today that it priced its upsized initial public offering of 20,000,000 units at $10.00 per unit. The units will be listed on the Nasdaq Global Market (“Nasdaq”) an...